Chart Of The Day: Moderna Slated For New All-Time Highs

 | Jun 15, 2021 09:34AM ET

Moderna (NASDAQ:MRNA) dropped over 5% on Monday after Novavax (NASDAQ:NVAX) published data from the trials of its COVID-19 vaccine, NVX-CoV2373, stating it had a 90.4% efficacy rate in the third phase trial of a near-30,000-participant study in the US and Mexico. The vaccine also demonstrated 100% proof against moderate and even severe conditions of the virus. Finally, it showed little side effect.

The drug maker plans to apply for emergency authorization in the US in the third quarter. The company said it could produce 150 million doses per month by the end of the year.

With many countries still without the vaccine, Novavax could provide competition to Moderna’s growth. On the other hand, Moderna is well ahead of the game, having already asked US health regulators for approval to administer its vaccine on teens ages 12 to 17.

Despite the Novavax news, Moderna withstood a selloff. As we can see in the chart, while Moderna’s share slid on the announcement, the stock has pared almost twice the loss.